Azor, Israel

Moshe Elazar

This inventor holds 2 USPTO granted patents and 4 published patent applications and 1 EPO patent. Top assignees: Enopace Biomedical Ltd., Vascular Dynamics, Inc.. Active years: 2016-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Moshe Elazar. Retrieved from https://idiyas.com/inventor/moshe-elazar-5v7whog3

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 2 

% Patents Active = 100.0

 

Average Co-Inventor Count = 8.9

ph-index = 2

Forward Citations = 25(Granted Patents)


Company Filing History:


Years Active: 2016-2017

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Journey of Moshe Elazar

Introduction: Moshe Elazar is a renowned inventor hailing from Azor, Israel, known for his groundbreaking contributions to various fields through his inventive spirit and dedication to innovation.

Latest Patents: Moshe Elazar holds several patents in diverse areas, showcasing his versatility and creativity in inventing new solutions to complex problems.

Career Highlights: Throughout his illustrious career, Moshe Elazar has consistently pushed the boundaries of innovation, with his inventions making a significant impact in industries such as technology, healthcare, and sustainability.

Collaborations: Moshe Elazar has collaborated with leading experts and organizations worldwide, fostering a culture of innovation and knowledge-sharing to drive progress and positive change.

Conclusion: Moshe Elazar's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors, leaving a lasting legacy in the world of inventions and patents.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…